Great Britain locks in indefinite CE recognition for medical devices
Patients in Great Britain will keep access to the vast majority of medical devices already approved for the European market after the government confirmed indefinite recognition of CE marked medical devices. The decision covers everything from insulin pumps and replacement joints to diagnostic tests and surgical equipment, and it removes the prospect of a separate, duplicate approval route for products already cleared for use in the EU.
For hospitals, manufacturers, and patients, the practical effect is immediate. Devices that already carry a CE mark can continue to reach the Great British market without another layer of pre-market assessment, helping protect supply chains in a sector where continuity matters as much as innovation.
Supply continuity and patient access drive the policy choice
The move follows a public consultation that ran from 16 February 2026 to 10 April 2026 and drew more than 1,000 responses from patients, healthcare organisations, industry, and others. That level of response signals how closely access to devices is tied to everyday clinical care. In diabetes clinics, orthopaedic theatres, radiology suites, and operating rooms, delays in device availability can affect treatment timetables long before any headline policy debate reaches the bedside.
More than 90% of medical devices registered for use in Great Britain currently carry a CE mark. Preserving recognition of those products avoids a cliff-edge scenario in which manufacturers would need to navigate a separate approval process just to maintain a familiar product on the shelf. For patients, the policy reduces the risk of disruption in care pathways that depend on steady access to established technologies.
This is especially relevant for in vitro diagnostic devices, where supply interruptions can affect screening, triage, and monitoring decisions. A delay in a diagnostic test can ripple through the system, slowing treatment decisions and increasing pressure on already stretched services.
UKCA remains the domestic route as oversight tightens
The decision does not replace the UKCA route. Instead, CE recognition sits alongside the domestic approval pathway for devices placed on the market in Great Britain, with UKCA continuing to operate as the local regulatory route. The UKCA system is being modernised through the pre-market statutory instrument, which will update the requirements devices must meet to obtain UKCA marking.
At the same time, the MHRA is keeping a firm post-market grip on safety. Strengthened surveillance and reporting requirements remain in place, and the agency will continue to oversee all devices on the UK market. Safety monitoring includes the Yellow Card scheme, along with collaboration with international partners to share safety information and act quickly when concerns emerge.
This combination matters clinically because device regulation does not end at the point of approval. A product can perform well in pre-market testing and still encounter problems once it enters routine use across diverse patient groups, hospitals, and home settings. Post-market intelligence is where rare failures, usability issues, manufacturing defects, and software-related risks often become visible.
A rapid reporting network is now part of the regulatory architecture, not an optional extra.
AI and software devices shape the next phase of regulation
The government is also looking beyond the present policy decision. It intends to seek enabling powers through primary legislation for a future licensing approach designed to fit a more modern regulatory framework, including software and AI medical devices. That direction reflects recommendations from the National Commission into the Regulation of AI in Healthcare.
The rationale is straightforward: a regulatory model built for static hardware alone may struggle to keep pace with adaptive software, algorithmic updates, and digital tools that can evolve after deployment. In practical terms, the challenge is not only whether a device works on day one, but how its performance changes after updates, data drift, or integration into new clinical workflows. A modernized system needs to respond to those realities without slowing access to useful innovation.
The policy also aligns with the government’s Life Sciences Sector Plan and 10 Year Health Plan. In regulatory terms, the aim is to secure supply, support rapid access to innovation, and provide a clear pathway for manufacturers working in the UK market. Predictability in regulation often determines whether a company invests, launches, or expands a product line in a given country. For patients, those business decisions translate into the speed at which new technologies appear in clinics and operating rooms.
Industry response centers on certainty and market stability
Industry leaders welcomed the long-term recognition of CE marking as a way to reduce duplication and improve investment certainty. The focus from manufacturers is predictable: if a device is already approved for Europe, a second approval route can add cost and delay without adding meaningful clinical value in every case. A stable framework can help preserve availability of medical technologies that NHS services and private providers rely on every day.
The policy sits within a wider ambition in the MHRA’s 2030 Strategy to expand reliance and recognition routes with trusted regulators, reduce regulatory burden, strengthen supply resilience, and support timely patient access. In effect, the UK is signaling that it wants to keep regulatory safeguards strong while avoiding unnecessary barriers that could slow the flow of devices into care settings.
Safety monitoring will remain the operational test
The central question now is not whether CE-marked devices can continue to enter Great Britain, but how effectively the MHRA can maintain oversight while broadening access. The government has said it will continue engaging with patients, clinicians, and industry as the arrangements are implemented, including engagement sessions with patient groups to explain the response and address questions on safety and oversight.
That engagement will matter because regulatory confidence depends on more than formal approval routes. Clinicians need to know that a device on the market has a credible safety net behind it, and patients need reassurance that access has not come at the expense of accountability. The MHRA’s task is to keep both promises in view at once: continuity of supply on one side, and active surveillance on the other.
The consultation outcome and the long-term recognition decision settle one major uncertainty, but the operational challenge now shifts to implementation, surveillance, and the modernization of the UKCA and future licensing framework. The next test will be whether those systems can keep pace with fast-moving device innovation while preserving the safety standards that govern every product on the market.